"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 6 | 0 | 6 |
| 2018 | 4 | 8 | 12 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2. Phys Chem Chem Phys. 2021 Jun 09; 23(22):12549-12558.
-
Opioid use disorder treatment for people experiencing homelessness: A scoping review. Drug Alcohol Depend. 2021 07 01; 224:108717.
-
Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19. Am J Manag Care. 2021 03; 27(3):91-92.
-
Efficacy of Naldemedine in the Management of Constipation in a Patient with Severe COVID-19 Receiving Mechanical Ventilation. J Palliat Med. 2021 05; 24(5):651-652.
-
Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. Drug Alcohol Depend. 2021 02 01; 219:108486.
-
COVID-19 and treating incarcerated populations for opioid use disorder. J Subst Abuse Treat. 2021 05; 124:108216.
-
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency. J Subst Abuse Treat. 2021 01; 120:108149.
-
Naltrexone a potential therapeutic candidate for COVID-19. J Biomol Struct Dyn. 2022 02; 40(3):963-970.
-
COVID-19, Medication-Assisted Treatment, and Increased Risk for Further Respiratory Depression. Am J Psychiatry. 2020 07 01; 177(7):636.
-
The Use of Naltrexone in Dermatology. Current Evidence and Future Directions. Curr Drug Targets. 2019; 20(10):1058-1067.